TRILUMINATE Pivotal - 2-year update EuroPCR 25, presented by G. Singh
The TRILUMINATE Pivotal trial demonstrated that TriClip™ TEER was superior to medical therapy alone at reducing Heart Failure Hospitalization (HFH) risk at 2 years, while confirming its exceptional safety and quality of life improvement
LEARN MORE:
Related Resources
Poster: Primary MR in the Very Elderly
Prognosis of TR after MitraClip for MR
bRIGHT 2-year real-world outcomes
Navitor 5-years data from CRT
Tendyne expanded clinical study | PCR LV 2025
EXPAND G4 clinical data release | PCR LV 2025
bRIGHT clinical data release | PCR LV 2025
The standard of caring for TR
TEER G5 Brochure 2025
TRENDING TOPICS
Navitor 5-years data from CRT
bRIGHT clinical data release | PCR LV 2025
EXPAND G4 clinical data release | PCR LV 2025
